Product image of Meriofert (Follicle-Stimulating Hormone, Luteinising Hormone) supplied by GNH India

Meriofert

Active Ingredient:
Follicle-Stimulating Hormone, Luteinising Hormone
Origin:
EU

Meriofert (Follicle-Stimulating Hormone, Luteinising Hormone)

Follicle‑Stimulating Hormone; Luteinising Hormone, the active ingredient in Meriofert, is a gonadotropin presented as an injectable solution for intramuscular or subcutaneous use. It is used to treat infertility caused by anovulation, to support ovarian stimulation in assisted reproductive technologies, and to manage hypogonadotropic hypogonadism.

GNH India supplies Meriofert as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Ibsa Farmaceutici Italia

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Meriofert is a gonadotropin used in reproductive medicine to stimulate ovarian function.

  • Infertility due to anovulation: promotes follicular development and ovulation.
  • Assisted reproductive technology (e.g., IVF) ovarian stimulation: enhances multiple follicle growth for egg retrieval.
  • Hypogonadotropic hypogonadism: replaces deficient endogenous FSH and LH to restore normal gonadal activity.

How It Works

  • Meriofert contains recombinant follicle‑stimulating hormone and luteinising hormone that bind to their respective FSH and LH receptors on ovarian granulosa and theca cells. Activation of these G‑protein‑coupled receptors stimulates intracellular cAMP production, leading to follicular maturation, estradiol synthesis, and luteinisation, thereby facilitating ovulation and supporting the luteal phase.

Side Effects

Administration of Meriofert may be associated with a range of adverse reactions, which are generally classified by frequency and severity.

Common Side Effects

  • Injection site pain or erythema: mild discomfort at the injection site.
  • Abdominal bloating or discomfort: transient gastrointestinal symptoms.
  • Headache: mild to moderate intensity.
  • Nausea: occasional mild nausea.

Serious or Rare Side Effects

  • Ovarian hyperstimulation syndrome (OHSS): potentially severe fluid shift and thromboembolic risk.
  • Multiple pregnancy: increased risk of twins or higher‑order gestations.
  • Severe allergic reaction: anaphylaxis, urticaria, or angioedema.

Precautions & Warnings

Before prescribing Meriofert, clinicians should consider several precautionary measures to ensure safe use.

  • Assess baseline ovarian reserve: evaluate antral follicle count and hormone levels.
  • Monitor estradiol levels during stimulation: adjust dose to avoid excessive response.
  • Perform ultrasound monitoring of follicular development: detect early signs of OHSS.
  • Review concomitant medications: avoid agents that may exacerbate ovarian response.
  • Contraindications: do not use in patients with known hypersensitivity to gonadotropins or active ovarian cysts.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Meriofert can interact with other agents that influence reproductive hormone pathways or coagulation.

Major Interactions (Avoid)

  • GnRH agonists or antagonists: may alter the intended stimulation protocol.
  • High‑dose estrogen therapy: can suppress endogenous gonadotropin response.
  • Anticoagulants: increased risk of bleeding at injection sites.

Moderate Interactions (Monitor Closely)

  • Oral contraceptives: may require a washout period before initiating therapy.
  • Thyroid hormone replacement: monitor thyroid function as gonadotropins can affect hormone metabolism.
  • Diuretics: may mask early signs of OHSS; monitor fluid balance.

Frequently Asked Questions

Meriofert is prescribed to treat infertility caused by anovulation, to stimulate the ovaries during assisted reproductive technologies such as in‑vitro fertilisation, and to replace deficient gonadotropins in patients with hypogonadotropic hypogonadism.

Both hormones bind to specific receptors on ovarian cells. FSH promotes growth and maturation of ovarian follicles, while LH triggers ovulation and supports luteal phase function. Together they coordinate the hormonal cascade required for successful egg release and preparation of the uterus.

The dose of Meriofert is individualized. A qualified prescriber determines the amount, frequency and duration based on the patient’s ovarian reserve, treatment protocol and response to monitoring.

Meriofert is intended for use before conception to achieve pregnancy. Its safety has not been established for use during an established pregnancy or while breastfeeding, and it should only be used under specialist supervision if pregnancy occurs.

To order Meriofert, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and necessary import documentation.

Meriofert combines recombinant FSH and LH in a single injectable formulation, offering the convenience of a dual‑hormone preparation. Compared with separate FSH‑only products, it may reduce the number of injections needed, while providing the LH activity that can be beneficial for certain stimulation protocols.

Meriofert must be stored at 2‑8 °C (refrigerated). Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the product to maintain potency.

Meriofert is given by a trained healthcare professional as an intramuscular or subcutaneous injection. The injection site is typically the thigh or abdomen, and the exact technique follows the prescribing physician’s protocol.

The most serious risks include ovarian hyperstimulation syndrome, which can cause rapid fluid shifts and thromboembolic complications, and the possibility of multiple pregnancy. Severe allergic reactions such as anaphylaxis are also rare but require immediate medical attention.

Meriofert should not be used in individuals with known hypersensitivity to any gonadotropin component, active ovarian cysts, uncontrolled thyroid disease, or in patients where ovarian stimulation is contraindicated, such as certain cancers or severe systemic illness.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Follicle-Stimulating Hormone, Luteinising Hormone

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT